NIH #5R01AI171984-02
The roles of genetics, hormones, and gender in sexually dimorphic immune response
Expiring Soon
- Amount
- $612K
- Period
- 2022-09-01 → 2026-08-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at VAN ANDEL RESEARCH INSTITUTE
NIH #1R01AI171984-01
The roles of genetics, hormones, and gender in sexually dimorphic immune response
Expiring Soon
- Amount
- $636K
- Period
- 2022-09-01 → 2026-08-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at VAN ANDEL RESEARCH INSTITUTE
NIH #5R42CA281707-03
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
Expiring Soon
- Amount
- $1.0M
- Period
- 2023-08-08 → 2026-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #4R42CA281707-02
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
Expiring Soon
- Amount
- $1.0M
- Period
- 2023-08-08 → 2026-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #5R01CA257610-05
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
Active
- Amount
- $690K
- Period
- 2021-02-09 → 2027-01-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #1R03CA290259-01
Dissecting the role of germline genetic variation and viral exposures as determinants of hematological disease predisposition
- Amount
- $336K
- Period
- 2024-07-01 → 2026-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at VAN ANDEL RESEARCH INSTITUTE
NIH #5R01CA257610-04
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
- Amount
- $655K
- Period
- 2021-02-09 → 2026-01-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5R01CA257610-03
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
- Amount
- $676K
- Period
- 2021-02-09 → 2026-01-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5R01CA257610-02
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
- Amount
- $676K
- Period
- 2021-02-09 → 2026-01-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #1R01CA257610-01
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
- Amount
- $706K
- Period
- 2021-02-09 → 2026-01-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5R01AI171984-03
The roles of genetics, hormones, and gender in sexually dimorphic immune response
- Amount
- $249K
- Period
- 2022-09-01 → 2025-03-03
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at VAN ANDEL RESEARCH INSTITUTE
NIH #1R42CA281707-01
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
- Amount
- $400K
- Period
- 2023-08-08 → 2024-01-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #5R44CA233128-03
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy
- Amount
- $893K
- Period
- 2018-09-14 → 2021-10-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #4R44CA233128-02
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy
- Amount
- $1.0M
- Period
- 2018-09-14 → 2021-04-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #1R44CA233128-01
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy
- Amount
- $241K
- Period
- 2018-09-14 → 2019-04-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #1R41CA203457-01A1
Nanoparticle Delivery System for Ewing Sarcoma Treatment
- Amount
- $241K
- Period
- 2016-04-15 → 2018-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at NANOVALENT PHARMACEUTICALS, INC.
NIH #5RC2CA148216-02
Translation of Predictive Cancer Biomarkers into Clinical Practice
- Amount
- $1.3M
- Period
- 2009-09-29 → 2012-08-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #1RC2CA148216-01
Translation of Predictive Cancer Biomarkers into Clinical Practice
- Amount
- $1.6M
- Period
- 2009-09-29 → 2011-08-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #2P30CA014089-31
Microarray Core Facility
- Amount
- $179K
- Period
- 2006-04-21 → 2010-11-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5U01CA114757-05
Diagnostic and Prognostic Sarcoma Signatures
- Amount
- $1.7M
- Period
- 2005-09-27 → 2010-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA114757-04
Diagnostic and Prognostic Sarcoma Signatures
- Amount
- $1.7M
- Period
- 2005-09-27 → 2010-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA114757-03
Diagnostic and Prognostic Sarcoma Signatures
- Amount
- $1.7M
- Period
- 2005-09-27 → 2010-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA114757-02
Diagnostic and Prognostic Sarcoma Signatures
- Amount
- $1.7M
- Period
- 2005-09-27 → 2010-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #1U01CA114757-01
Diagnostic and Prognostic Sarcoma Signatures
- Amount
- $1.7M
- Period
- 2005-09-27 → 2010-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA088199-05
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE
- Amount
- $982K
- Period
- 2000-09-20 → 2007-01-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA088199-04
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE
- Amount
- $1.2M
- Period
- 2000-09-20 → 2005-01-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA088199-03
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE
- Amount
- $1.7M
- Period
- 2000-09-20 → 2005-01-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5U01CA088199-02
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE
- Amount
- $1.4M
- Period
- 2000-09-20 → 2005-01-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #1U01CA088199-01
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE
- Amount
- $715K
- Period
- 2000-09-20 → 2005-01-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES
NIH #5P30CA014089-35
Microarray Core Facility
- Amount
- $407K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~6 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5P30CA014089-34
Microarray Core Facility
- Amount
- $413K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~6 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5P30CA014089-33
Microarray Core Facility
- Amount
- $353K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~5 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA
NIH #5P30CA014089-32
Microarray Core Facility
- Amount
- $397K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~6 students
Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA